MoonLake Immunotherapeutics (NASDAQ:MLTX)’s traded shares stood at 0.81 million during the last session, with the company’s beta value hitting 1.32. At the close of trading, the stock’s price was $43.81, to imply an increase of 5.64% or $2.34 in intraday trading. The MLTX share’s 52-week high remains $64.98, putting it -48.32% down since that peak but still an impressive 14.29% since price per share fell to its 52-week low of $37.55. The company has a valuation of $2.80B, with an average of 0.49 million shares in intraday trading volume over the past 10 days and average of 252.33K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for MoonLake Immunotherapeutics (MLTX), translating to a mean rating of 1.00. Of 6 analyst(s) looking at the stock, 0 analyst(s) give MLTX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.62.
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
After registering a 5.64% upside in the last session, MoonLake Immunotherapeutics (MLTX) has traded red over the past five days. The 5-day price performance for the stock is -5.41%, and -17.31% over 30 days. With these gigs, the year-to-date price performance is -19.10%. Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) saw shorts transact 8.08 million shares and set a 41.54 days time to cover.
The extremes give us $62 and $100 for target low and target high price respectively. As such, MLTX has been trading -128.26% off suggested target high and -41.52% from its likely low.
MoonLake Immunotherapeutics (MLTX) estimates and forecasts
Looking at statistics comparing MoonLake Immunotherapeutics share performance against respective industry, we note that the company has underperformed competitors. MoonLake Immunotherapeutics (MLTX) shares are -2.69% down over the last 6 months, with its year-to-date growth rate lower than industry average at -139.73% against 16.60%.
MLTX Dividends
MoonLake Immunotherapeutics has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
MoonLake Immunotherapeutics insiders hold 15.22% of total outstanding shares, with institutional holders owning 98.13% of the shares at 115.76% float percentage. In total, 98.13% institutions holds shares in the company, led by BVF INC/IL. As of 2024-06-30, the company held over 21.75 million shares (or 34.7258% of shares), all amounting to roughly $956.4 million.
The next major institution holding the largest number of shares is CORMORANT ASSET MANAGEMENT, LP with 8.49 million shares, or about 13.5609% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $373.49 million.
We also have Price (T.Rowe) Health Sciences Fund and Fidelity Select Portfolios – Health Care as the top two Mutual Funds with the largest holdings of the MoonLake Immunotherapeutics (MLTX) shares. Going by data provided on Sep 30, 2024 , Price (T.Rowe) Health Sciences Fund holds roughly 1.31 shares. This is just over 2.07% of the total shares, with a market valuation of $57.31 million. Data from the same date shows that the other fund manager holds a little less at 690.0, or 1.09% of the shares, all valued at about 30.23 million.
